相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
M. S. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
DR5 receptor mediates anoikis in human colorectal carcinoma cell lines
Luciana M. Laguinge et al.
CANCER RESEARCH (2008)
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
C. Adams et al.
CELL DEATH AND DIFFERENTIATION (2008)
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
Sebastien J. Hotte et al.
CLINICAL CANCER RESEARCH (2008)
Making progress against cancer in Europe in 2008
Tit Albreht et al.
EUROPEAN JOURNAL OF CANCER (2008)
TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development
Anne Grosse-Wilde et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
To kill a tumor cell: the potential of proapoptotic receptor agonists
Avi Ashkenazi et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
TRAU-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis
Niklas Finnberg et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
Avi Ashkenazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Anthony G. Letai
NATURE REVIEWS CANCER (2008)
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
Dylan Daniel et al.
BLOOD (2007)
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2007)
被撤回的出版物: Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase, inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation (Retracted Article. See vol 197, pg 4859, 2016)
Stavroula Baritaki et al.
JOURNAL OF IMMUNOLOGY (2007)
MCL-1 as a buffer for proapoptotic BCL-2 family members during TRAIL-induced apoptosis - A mechanistic basis for sorafenib (bay 43-9006)-induced trail sensitization
Xue Wei Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with mcl-1 and cFLIPL down-regulation
Roberto R. Rosato et al.
CANCER RESEARCH (2007)
LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization
T. W. Poh et al.
CELL DEATH AND DIFFERENTIATION (2007)
Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding
Lianghua Bin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
Klaus W. Wagner et al.
NATURE MEDICINE (2007)
Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients
Gustave J. Ullenhag et al.
CLINICAL CANCER RESEARCH (2007)
Who should be sent for genetic testing in hereditary colorectal cancer syndromes?
Henry T. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1
Nicholas D. Huntington et al.
NATURE IMMUNOLOGY (2007)
Reduction of TRAIL-induced McI-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death
M. Stacey Ricci et al.
CANCER CELL (2007)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model
Liang Zhang et al.
CANCER LETTERS (2007)
Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
Susan L. Kohlhaas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis
Anni I. Nieminen et al.
EMBO JOURNAL (2007)
Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling
Christine Feig et al.
EMBO JOURNAL (2007)
Apoptosis: A review of programmed cell death
Susan Elmore
TOXICOLOGIC PATHOLOGY (2007)
Current concepts in apoptosis: The physiological suicide program revisited
Indrajit Chowdhury et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2006)
Death-receptor activation halts clathrin-dependent endocytosis
Cary D. Austin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: A phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells
SE Hamilton et al.
NATURE IMMUNOLOGY (2006)
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs
TM Ganten et al.
CLINICAL CANCER RESEARCH (2006)
The role of receptor internalization in CD95 signaling
KH Lee et al.
EMBO JOURNAL (2006)
The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma
DJ Grunhagen et al.
CANCER (2006)
Apoptosis: a relevant tool for anticancer therapy
A. Russo et al.
ANNALS OF ONCOLOGY (2006)
Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme
Amith Panner et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death
YB Guo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis
L Clancy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor
S Ray et al.
APOPTOSIS (2005)
Caspase family proteases and apoptosis
TJ Fan et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2005)
Pharmacological manipulation of Bcl-2 family members to control cell death
A Letai
JOURNAL OF CLINICAL INVESTIGATION (2005)
Caspases: pharmacological manipulation of cell death
IN Lavrik et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death
GV Georgakis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells
ML Hyer et al.
CANCER RESEARCH (2005)
The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
BL Hylander et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis
DA Sharp et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma
LJ Zhu et al.
MOLECULAR CANCER THERAPEUTICS (2005)
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L Pukac et al.
BRITISH JOURNAL OF CANCER (2005)
Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor related apoptosis-inducing ligand receptor 2
K Motoki et al.
CLINICAL CANCER RESEARCH (2005)
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
EM Janssen et al.
NATURE (2005)
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
LD Zhang et al.
CANCER GENE THERAPY (2005)
Synergistic inhibition of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human pancreatic β cells by Bcl-2 and X-linked inhibitor of apoptosis
DW Ou et al.
HUMAN IMMUNOLOGY (2005)
RAS, MYC, and sensitivity to tumor necrosis factor-α-related apoptosis-inducing ligand-induced apoptosis
Y Wang et al.
CANCER RESEARCH (2005)
Apoptosis in the development and treatment of cancer
R Gerl et al.
CARCINOGENESIS (2005)
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution
RF Kelley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts
A El-Zawahry et al.
BMC CANCER (2005)
Death to the bad guys: Targeting cancer via Apo2L/TRAIL
S Bouralexis et al.
APOPTOSIS (2005)
Tumor necrosis factor: An apoptosis JuNKie?
EE Varfolomeev et al.
CELL (2004)
Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death
JR Muppidi et al.
NATURE IMMUNOLOGY (2004)
Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms
S Shankar et al.
PROSTATE (2004)
Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil
SL Wang et al.
CANCER RESEARCH (2004)
A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death
L Li et al.
SCIENCE (2004)
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
S Nakata et al.
ONCOGENE (2004)
Targeting death receptors in cancer with Apo2/TRAIL
SK Kelley et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL
R Ravi et al.
CANCER RESEARCH (2004)
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival
H Jin et al.
CANCER RESEARCH (2004)
TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice
CH Hao et al.
CANCER RESEARCH (2004)
TRAIL-R as a negative regulator of innate immune cell responses
GE Diehl et al.
IMMUNITY (2004)
Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies
EK Rowinsky
CLINICAL CANCER RESEARCH (2004)
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity
MS Ricci et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
TRAIL and apoptosis induction by TNF-family death receptors
SL Wang et al.
ONCOGENE (2003)
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
SH Kaufmann et al.
ONCOGENE (2003)
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells
TR Johnson et al.
ONCOGENE (2003)
Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes
O Micheau et al.
CELL (2003)
Cytogenetic evolution of follicular lymphoma
A Viardot et al.
SEMINARS IN CANCER BIOLOGY (2003)
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
A Almasan et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
The role of the Bcl-2 protein family in cancer
L Coultas et al.
SEMINARS IN CANCER BIOLOGY (2003)
A unified model for apical caspase activation
KM Boatright et al.
MOLECULAR CELL (2003)
The CD95(APO-1/Fas) DISC and beyond
ME Peter et al.
CELL DEATH AND DIFFERENTIATION (2003)
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc et al.
CELL DEATH AND DIFFERENTIATION (2003)
The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet
G van Loo et al.
CELL DEATH AND DIFFERENTIATION (2002)
Live or let die: The cell's response to p53
KH Vousden et al.
NATURE REVIEWS CANCER (2002)
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
S Fulda et al.
NATURE MEDICINE (2002)
Cloning and expression of rat caspase-6 and its localization in renal ischemia/reperfusion injury
AB Singh et al.
KIDNEY INTERNATIONAL (2002)
Sensitivity to apoptosis signal, clearance rate, and ultrastructure of Fas ligand-induced apoptosis in in vivo adult cardiac cells
K Hayakawa et al.
CIRCULATION (2002)
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
NATURE REVIEWS CANCER (2002)
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors
H Xiang et al.
ONCOGENE (2002)
Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis
F Guo et al.
BLOOD (2002)
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
S Fulda et al.
ONCOGENE (2002)
Death and anti-death: Tumour resistance to apoptosis
FH Igney et al.
NATURE REVIEWS CANCER (2002)
NF-kappa B at the crossroads of life and death
M Karin et al.
NATURE IMMUNOLOGY (2002)
Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein
S Frese et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2002)
Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs
S Vignati et al.
EUROPEAN JOURNAL OF CANCER (2002)
Activation of caspase-8 in the Alzheimer's disease brain
TT Rohn et al.
NEUROBIOLOGY OF DISEASE (2001)
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling
WS El-Deiry
CELL DEATH AND DIFFERENTIATION (2001)
Regulation of lymphocyte proliferation and death by flip
M Thome et al.
NATURE REVIEWS IMMUNOLOGY (2001)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
CS Mitsiades et al.
BLOOD (2001)
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
K Ichikawa et al.
NATURE MEDICINE (2001)
Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells
M Cuello et al.
GYNECOLOGIC ONCOLOGY (2001)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
D Lawrence et al.
NATURE MEDICINE (2001)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis
MJ Smyth et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
K Takeda et al.
NATURE MEDICINE (2001)
Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL
JL Bodmer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
M Jo et al.
NATURE MEDICINE (2000)
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL
SG Hymowitz et al.
BIOCHEMISTRY (2000)
Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane
R Eskes et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
